Leptoprol (Leuprorelin)

Leuprorelin is a synthetic GnRH analogue. Continuous exposure desensitizes pituitary GnRH receptors, leading to a sharp decline in luteinizing hormone and follicle‑stimulating hormone release. The downstream effect is a marked reduction in testosterone and estradiol levels, which underpins its therapeutic action in hormone‑sensitive conditions.

The appropriate dose of Leptoprol is set by the prescribing clinician based on the specific indication, patient weight, disease severity, and treatment protocol. Dosage regimens vary between oncology, gynecologic, and pediatric applications, and the prescriber will tailor the schedule to achieve optimal hormone suppression while monitoring safety.

Leptoprol is contraindicated in pregnancy because it suppresses sex hormone production essential for fetal development. It is also not recommended during breastfeeding, as leuprorelin may pass into breast milk and affect the infant's hormonal balance. Women of child‑bearing potential should use effective contraception during treatment.

To request Leptoprol, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Leptoprol (leuprorelin) and goserelin belong to the same GnRH‑agonist class and achieve similar hormone‑suppression effects. Differences lie mainly in formulation, dosing frequency, and pharmacokinetic profiles; leuprorelin is often available in daily or monthly injectable forms, whereas goserelin is commonly supplied as a monthly depot. Choice depends on clinical preference, patient convenience and specific regulatory approvals.

Leptoprol should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, follow the manufacturer’s guidance before administration.

Leptoprol is supplied as a sterile solution for subcutaneous injection. A healthcare professional prepares the dose according to the prescribed regimen and injects it into the subcutaneous tissue, typically in the abdomen or thigh. The injection site should be rotated to minimize local irritation.

Serious risks include cardiovascular events such as myocardial infarction, severe allergic reactions including anaphylaxis, and significant loss of bone mineral density that can lead to osteoporosis. Patients should be monitored regularly for cardiac symptoms, allergic signs, and bone health, especially during long‑term treatment.

Leptoprol is contraindicated in patients with known hypersensitivity to leuprorelin or any excipients, those with uncontrolled cardiovascular disease, and individuals who are pregnant or breastfeeding. Caution is also advised for patients with severe osteoporosis, active liver disease, or a history of pituitary apoplexy.